144 related articles for article (PubMed ID: 3620309)
1. Cell cycle phase perturbations by 6-diazo-5-oxo-L-norleucine and acivicin in normal and neoplastic human cell lines.
Huber KR; Mayer EP; Mitchell DF; Roberts J
Br J Cancer; 1987 Jun; 55(6):653-6. PubMed ID: 3620309
[No Abstract] [Full Text] [Related]
2. Uptake of glutamine antimetabolites 6-diazo-5-oxo-L-norleucine (DON) and acivicin in sensitive and resistant tumor cell lines.
Huber KR; Rosenfeld H; Roberts J
Int J Cancer; 1988 May; 41(5):752-5. PubMed ID: 3366493
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of antitumor activity of glutamine antagonists 6-diazo-5-oxo-L-norleucine and acivicin in cell culture by glutaminase-asparaginase.
Rosenfeld H; Roberts J
Cancer Res; 1981 Apr; 41(4):1324-8. PubMed ID: 7214322
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of 6-diazo-5-oxo-L-norleucine (DON, NSC-7365) in advanced large bowel carcinoma.
Rubin J; Sorensen S; Schutt AJ; van Hazel GA; O'Connell MJ; Moertel CG
Am J Clin Oncol; 1983 Jun; 6(3):325-6. PubMed ID: 6846250
[No Abstract] [Full Text] [Related]
5. Efficacy of 6-diazo-5-oxo-L-norleucine and N-[N-gamma-glutamyl-6-diazo-5-oxo-norleucinyl]-6-diazo-5-oxo-norleucine against experimental tumors in conventional and nude mice.
Ovejera AA; Houchens DP; Catane R; Sheridan MA; Muggia FM
Cancer Res; 1979 Aug; 39(8):3220-4. PubMed ID: 572261
[TBL] [Abstract][Full Text] [Related]
6. Azaserine, DON, and azotomycin: three diazo analogs of L-glutamine with clinical antitumor activity.
Catane R; Von Hoff DD; Glaubiger DL; Muggia FM
Cancer Treat Rep; 1979 Jun; 63(6):1033-8. PubMed ID: 380801
[TBL] [Abstract][Full Text] [Related]
7. Metabolism of glutamine in erythrocytes infected with the human malaria parasite: Plasmodium falciparum.
Vilmont M; Azoulay M; Frappier F
Ann Parasitol Hum Comp; 1990; 65(4):162-6. PubMed ID: 1982204
[TBL] [Abstract][Full Text] [Related]
8. Inactivation of rat renal phosphate-dependent glutaminase with 6-diazo-5-oxo-L-norleucine. Evidence for interaction at the glutamine binding site.
Shapiro RA; Clark VM; Curthoys NP
J Biol Chem; 1979 Apr; 254(8):2835-8. PubMed ID: 429321
[TBL] [Abstract][Full Text] [Related]
9. Acivicin: a new glutamine antagonist in clinical trials.
O'Dwyer PJ; Alonso MT; Leyland-Jones B
J Clin Oncol; 1984 Sep; 2(9):1064-71. PubMed ID: 6470756
[No Abstract] [Full Text] [Related]
10. Comparison of the hydrolysis and the covalent binding of 6-diazo-5-oxo-L-[6-14C]norleucine by rat renal phosphate-dependent glutaminase.
Clark VM; Shapiro RA; Curthoys NP
Arch Biochem Biophys; 1982 Jan; 213(1):232-9. PubMed ID: 6120680
[No Abstract] [Full Text] [Related]
11. The role of glutamine and glucose analogues in metabolic inhibition of human myeloid leukaemia in vitro.
Griffiths M; Keast D; Patrick G; Crawford M; Palmer TN
Int J Biochem; 1993 Dec; 25(12):1749-55. PubMed ID: 8138012
[TBL] [Abstract][Full Text] [Related]
12. The inhibition by 6-diazo-5-oxo-l-norleucine of glutamine catabolism of the cultured human lymphoblast.
Willis RC; Seegmiller JE
J Cell Physiol; 1977 Dec; 93(3):375-82. PubMed ID: 22551
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic effects of acivicin and N-(phosphonacetyl)-L-aspartic acid in a biochemically designed trial against a N-(phosphonacetyl)-L-aspartic acid-resistant variant of the Lewis lung carcinoma.
Kensler TW; Reck LJ; Cooney DA
Cancer Res; 1981 Mar; 41(3):905-9. PubMed ID: 7459876
[No Abstract] [Full Text] [Related]
14. Mechanism of resistance of a variant of P388 leukemia to L-(alpha S,5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (acivicin).
Jayaram HN; Ardalan B; Deas M; Johnson RK
Cancer Res; 1985 Jan; 45(1):207-12. PubMed ID: 2578092
[TBL] [Abstract][Full Text] [Related]
15. Acivicin reduces tumor growth during total parenteral nutrition (TPN).
Chance WT; Cao L; Nelson JL; Foley-Nelson T; Fischer JE
Surgery; 1987 Aug; 102(2):386-94. PubMed ID: 3112985
[TBL] [Abstract][Full Text] [Related]
16. The rediscovery of DON (6-diazo-5-oxo-L-norleucine).
Kisner DL; Catane R; Muggia FM
Recent Results Cancer Res; 1980; 74():258-63. PubMed ID: 7192426
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxic mechanisms of glutamine antagonists in mouse L1210 leukemia.
Lyons SD; Sant ME; Christopherson RI
J Biol Chem; 1990 Jul; 265(19):11377-81. PubMed ID: 2358467
[TBL] [Abstract][Full Text] [Related]
18. Phase II study on DON in patients with previously treated advanced lung cancer.
Eagan RT; Frytak S; Nichols WC; Creagan ET; Ingle JN
Cancer Treat Rep; 1982 Aug; 66(8):1665-6. PubMed ID: 6286122
[No Abstract] [Full Text] [Related]
19. Phase II evaluation of DON (6-diazo-5-oxo-L-norleucine) in patients with advanced colorectal carcinoma.
Lynch G; Kemeny N; Casper E
Am J Clin Oncol; 1982 Oct; 5(5):541-3. PubMed ID: 7180833
[TBL] [Abstract][Full Text] [Related]
20. Response of tumor and host to hyperalimentation and antiglutamine treatments.
Chance WT; Cao LQ; Fischer JE
JPEN J Parenter Enteral Nutr; 1990; 14(2):122-8. PubMed ID: 2112618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
